Prevalence of and risk factors for resistance to second-line drugs in people with multidrug-resistant tuberculosis in eight countries: a prospective cohort study.

Extensive drug resistance acquired during treatment of multidrug-resistant tuberculosis. Clin Infect Dis (2014) 5.60

Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement. Eur Respir J (2014) 2.28

Treatment practices, outcomes, and costs of multidrug-resistant and extensively drug-resistant tuberculosis, United States, 2005-2007. Emerg Infect Dis (2014) 2.03

Sputum culture conversion as a prognostic marker for end-of-treatment outcome in patients with multidrug-resistant tuberculosis: a secondary analysis of data from two observational cohort studies. Lancet Respir Med (2015) 1.72

The heterogeneous evolution of multidrug-resistant Mycobacterium tuberculosis. Trends Genet (2012) 1.41

Principles for designing future regimens for multidrug-resistant tuberculosis. Bull World Health Organ (2013) 1.17

Resistance to second-line drugs in multidrug-resistant tuberculosis. Lancet (2013) 1.14

Target product profile of a molecular drug-susceptibility test for use in microscopy centers. J Infect Dis (2015) 1.08

Sustained release formulation of an anti-tuberculosis drug based on para-amino salicylic acid-zinc layered hydroxide nanocomposite. Chem Cent J (2013) 1.08

Predictors of pulmonary tuberculosis treatment outcomes in South Korea: a prospective cohort study, 2005-2012. BMC Infect Dis (2014) 1.04

Unexpected high levels of multidrug-resistant tuberculosis present new challenges for tuberculosis control. Lancet (2012) 1.03

Thioridazine pharmacokinetic-pharmacodynamic parameters "Wobble" during treatment of tuberculosis: a theoretical basis for shorter-duration curative monotherapy with congeners. Antimicrob Agents Chemother (2013) 1.02

Extensively drug-resistant tuberculosis: epidemiology and management. Clin Epidemiol (2014) 1.02

Enhancing hit identification in Mycobacterium tuberculosis drug discovery using validated dual-event Bayesian models. PLoS One (2013) 1.01

Association between Regimen Composition and Treatment Response in Patients with Multidrug-Resistant Tuberculosis: A Prospective Cohort Study. PLoS Med (2015) 0.99

Improved survival in multidrug-resistant tuberculosis patients receiving integrated tuberculosis and antiretroviral treatment in the SAPiT Trial. Int J Tuberc Lung Dis (2014) 0.98

Additional drug resistance of multidrug-resistant tuberculosis in patients in 9 countries. Emerg Infect Dis (2015) 0.98

Resistance to second-line drugs in multidrug-resistant tuberculosis. Lancet (2013) 0.95

Incidence and risk factors for extensively drug-resistant tuberculosis in Delhi region. PLoS One (2013) 0.94

Multidrug-Resistant Tuberculosis Treatment Outcomes in Relation to Treatment and Initial Versus Acquired Second-Line Drug Resistance. Clin Infect Dis (2015) 0.94

Multidrug and extensively drug-resistant tuberculosis in Canada 1997-2008: demographic and disease characteristics. PLoS One (2013) 0.93

Drug Susceptibility Patterns in MDR-TB Patients: Challenges for Future Regimen Design. A Cross-Sectional Study. PLoS One (2015) 0.91

Systematic review and meta-analysis of the efficacy and safety of therapy with linezolid containing regimens in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis. J Thorac Dis (2015) 0.91

Screening for pulmonary tuberculosis in HIV-infected individuals: AIDS Clinical Trials Group Protocol A5253. Int J Tuberc Lung Dis (2013) 0.91

Mortality among MDR-TB cases: comparison with drug-susceptible tuberculosis and associated factors. PLoS One (2015) 0.90

Weight gain and response to treatment for multidrug-resistant tuberculosis. Am J Trop Med Hyg (2013) 0.89

Pathogens hijack the epigenome: a new twist on host-pathogen interactions. Am J Pathol (2014) 0.88

A chemical proteomics approach to profiling the ATP-binding proteome of Mycobacterium tuberculosis. Mol Cell Proteomics (2013) 0.85

Favorable outcomes for multidrug and extensively drug resistant tuberculosis patients undergoing surgery. Ann Thorac Surg (2013) 0.85

Multidrug-resistant tuberculosis in Europe, 2010-2011. Emerg Infect Dis (2015) 0.84

A Novel Reporter Phage To Detect Tuberculosis and Rifampin Resistance in a High-HIV-Burden Population. J Clin Microbiol (2015) 0.84

Treatment outcomes among drug-susceptible tuberculosis patients in Latvia, 2006-2010. Public Health Action (2014) 0.83

First novel anti-tuberculosis drug in 40 years. Nat Biotechnol (2013) 0.83

Molecular and phenotypic characterization of multidrug-resistant Mycobacterium tuberculosis isolates resistant to kanamycin, amikacin, and capreomycin in China. Eur J Clin Microbiol Infect Dis (2014) 0.82

Efficacy of nitazoxanide against clinical isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother (2013) 0.82

DNA consensus sequence motif for binding response regulator PhoP, a virulence regulator of Mycobacterium tuberculosis. Biochemistry (2014) 0.82

Increased Vancomycin Susceptibility in Mycobacteria: a New Approach To Identify Synergistic Activity against Multidrug-Resistant Mycobacteria. Antimicrob Agents Chemother (2015) 0.81

Later emergence of acquired drug resistance and its effect on treatment outcome in patients treated with Standard Short-Course Chemotherapy for tuberculosis. BMC Pulm Med (2016) 0.81

Phenotypic and genotypic diversity in a multinational sample of drug-resistant Mycobacterium tuberculosis isolates. Int J Tuberc Lung Dis (2015) 0.80

Challenges and controversies in defining totally drug-resistant tuberculosis. Emerg Infect Dis (2012) 0.78

NMR Metabolomics Analysis of Parkinson's Disease. Curr Metabolomics (2015) 0.77

Unemployment in TB patients - ten-year observation at regional center of pulmonology in Bydgoszcz, Poland. Med Sci Monit (2014) 0.77

The structural modeling of the interaction between levofloxacin and the Mycobacterium tuberculosis gyrase catalytic site sheds light on the mechanisms of fluoroquinolones resistant tuberculosis in Colombian clinical isolates. Biomed Res Int (2014) 0.76

Major Challenges in Clinical Management of TB/HIV Coinfected Patients in Eastern Europe Compared with Western Europe and Latin America. PLoS One (2015) 0.76

Reply to Soman et al, Alffenaar et al, Metcalfe et al, and Raoult. Clin Infect Dis (2014) 0.75

Tradeoffs in Introduction Policies for the Anti-Tuberculosis Drug Bedaquiline: A Model-Based Analysis. PLoS Med (2016) 0.75

Implications of failure to routinely diagnose resistance to second-line drugs in patients with rifampicin-resistant tuberculosis on Xpert MTB/RIF: a multisite observational study. Clin Infect Dis (2017) 0.75

Genome sequencing and annotation of multidrug resistant Mycobacterium tuberculosis (MDR-TB) PR10 strain. Genom Data (2016) 0.75

Persistently high prevalence of primary resistance and multidrug resistance of tuberculosis in Heilongjiang Province, China. BMC Infect Dis (2016) 0.75

Resistance to second-line drugs in multidrug-resistant tuberculosis - Authors' reply. Lancet (2013) 0.75

Discordance across Phenotypic and Molecular Methods for Drug Susceptibility Testing of Drug-Resistant Mycobacterium tuberculosis Isolates in a Low TB Incidence Country. PLoS One (2016) 0.75

Impact of the Mycobaterium africanum West Africa 2 Lineage on TB Diagnostics in West Africa: Decreased Sensitivity of Rapid Identification Tests in The Gambia. PLoS Negl Trop Dis (2016) 0.75

A Web-Based Platform for Designing Vaccines against Existing and Emerging Strains of Mycobacterium tuberculosis. PLoS One (2016) 0.75

Determinants of multidrug-resistant tuberculosis in Henan province in China: a case control study. BMC Public Health (2016) 0.75

Low Levels of Extensively Drug-resistant Tuberculosis among Multidrug Resistant Tuberculosis Isolates and Their Relationship to Risk Factors: Surveillance in Tehran, Iran; 2006 to 2014. Osong Public Health Res Perspect (2017) 0.75

Direct observation therapy with appropriate treatment regimens was associated with a decline in second-line drug-resistant tuberculosis in Taiwan. Eur J Clin Microbiol Infect Dis (2013) 0.75

Asymmetric Structure of the Dimerization Domain of PhoR, a Sensor Kinase Important for the Virulence of Mycobacterium tuberculosis. ACS Omega (2017) 0.75

Prevalence and Molecular Characterization of Second-Line Drugs Resistance among Multidrug-Resistant Mycobacterium tuberculosis Isolates in Southwest of China. Biomed Res Int (2017) 0.75

First use of bedaquiline in a patient with XDR-TB in Singapore. BMJ Case Rep (2015) 0.75

Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lancet (2011) 16.49

Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature (2011) 13.25

Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis. Lancet (2010) 10.21

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med (2014) 10.10

Fatal and nonfatal outcomes, incidence of hypertension, and blood pressure changes in relation to urinary sodium excretion. JAMA (2011) 8.83

Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med (2012) 6.73

Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States. MMWR Recomm Rep (2005) 6.45

Worldwide emergence of extensively drug-resistant tuberculosis. Emerg Infect Dis (2007) 6.41

A glycolipid of hypervirulent tuberculosis strains that inhibits the innate immune response. Nature (2004) 6.29

Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. N Engl J Med (2003) 6.07

Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N Engl J Med (2012) 5.87

Prognostic accuracy of day versus night ambulatory blood pressure: a cohort study. Lancet (2007) 5.21

Early treatment outcomes and HIV status of patients with extensively drug-resistant tuberculosis in South Africa: a retrospective cohort study. Lancet (2010) 4.95

Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med (2014) 4.95

Tuberculous granulomas are hypoxic in guinea pigs, rabbits, and nonhuman primates. Infect Immun (2008) 4.93

The transcriptional responses of Mycobacterium tuberculosis to inhibitors of metabolism: novel insights into drug mechanisms of action. J Biol Chem (2004) 4.75

PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release. Science (2008) 4.74

Ambient air pollution exaggerates adipose inflammation and insulin resistance in a mouse model of diet-induced obesity. Circulation (2009) 4.71

Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLoS Med (2012) 4.69

Molecular detection of mutations associated with first- and second-line drug resistance compared with conventional drug susceptibility testing of Mycobacterium tuberculosis. Antimicrob Agents Chemother (2011) 4.55

Confronting the scientific obstacles to global control of tuberculosis. J Clin Invest (2008) 4.41

Tuberculosis - metabolism and respiration in the absence of growth. Nat Rev Microbiol (2005) 4.38

On the origin of leprosy. Science (2005) 4.22

Programmes and principles in treatment of multidrug-resistant tuberculosis. Lancet (2004) 4.21

Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis. Science (2011) 4.13

PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. Oncogene (2005) 4.07

Identification of a nitroimidazo-oxazine-specific protein involved in PA-824 resistance in Mycobacterium tuberculosis. Proc Natl Acad Sci U S A (2005) 3.97

Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial. Lancet (2002) 3.95

Variable-number tandem repeat typing of Mycobacterium tuberculosis isolates with low copy numbers of IS6110 by using mycobacterial interspersed repetitive units. J Clin Microbiol (2002) 3.88

Circulating MicroRNA-208b and MicroRNA-499 reflect myocardial damage in cardiovascular disease. Circ Cardiovasc Genet (2010) 3.75

Meropenem-clavulanate is effective against extensively drug-resistant Mycobacterium tuberculosis. Science (2009) 3.73

Feasibility and cost-effectiveness of standardised second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru. Lancet (2002) 3.67

Informatics tools to monitor progress and outcomes of patients with drug resistant tuberculosis in Peru. Proc AMIA Symp (2002) 3.51

Age and the epidemiology and pathogenesis of tuberculosis. Lancet (2010) 3.37

DnaE2 polymerase contributes to in vivo survival and the emergence of drug resistance in Mycobacterium tuberculosis. Cell (2003) 3.36

Multidrug-resistant tuberculosis management in resource-limited settings. Emerg Infect Dis (2006) 3.32

Tuberculosis burden in households of patients with multidrug-resistant and extensively drug-resistant tuberculosis: a retrospective cohort study. Lancet (2010) 3.32

Tuberculosis: what we don't know can, and does, hurt us. Science (2010) 3.29

Management of high blood pressure in children and adolescents: recommendations of the European Society of Hypertension. J Hypertens (2009) 3.13

Evaluation of a two-step approach for large-scale, prospective genotyping of Mycobacterium tuberculosis isolates in the United States. J Clin Microbiol (2005) 3.01

Mycobacterium tuberculosis growth at the cavity surface: a microenvironment with failed immunity. Infect Immun (2003) 3.01

Treatment outcomes and long-term survival in patients with extensively drug-resistant tuberculosis. Am J Respir Crit Care Med (2008) 2.92

Masked hypertension in diabetes mellitus: treatment implications for clinical practice. Hypertension (2013) 2.89

Contribution of the Mycobacterium tuberculosis MmpL protein family to virulence and drug resistance. Infect Immun (2005) 2.89

Elemental analysis of Mycobacterium avium-, Mycobacterium tuberculosis-, and Mycobacterium smegmatis-containing phagosomes indicates pathogen-induced microenvironments within the host cell's endosomal system. J Immunol (2005) 2.80

Neutrophils are the predominant infected phagocytic cells in the airways of patients with active pulmonary TB. Chest (2009) 2.78

Overexpression of the chromosomally encoded aminoglycoside acetyltransferase eis confers kanamycin resistance in Mycobacterium tuberculosis. Proc Natl Acad Sci U S A (2009) 2.77

Treatment outcomes of patients with multidrug-resistant and extensively drug-resistant tuberculosis according to drug susceptibility testing to first- and second-line drugs: an individual patient data meta-analysis. Clin Infect Dis (2014) 2.75

Significance of white-coat hypertension in older persons with isolated systolic hypertension: a meta-analysis using the International Database on Ambulatory Blood Pressure Monitoring in Relation to Cardiovascular Outcomes population. Hypertension (2012) 2.75

Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations. Proc Natl Acad Sci U S A (2010) 2.68

Prognostic value of reading-to-reading blood pressure variability over 24 hours in 8938 subjects from 11 populations. Hypertension (2010) 2.64

Combinatorial lead optimization of [1,2]-diamines based on ethambutol as potential antituberculosis preclinical candidates. J Comb Chem (2003) 2.63

The role of RelMtb-mediated adaptation to stationary phase in long-term persistence of Mycobacterium tuberculosis in mice. Proc Natl Acad Sci U S A (2003) 2.60

Diagnostic thresholds for ambulatory blood pressure monitoring based on 10-year cardiovascular risk. Circulation (2007) 2.59

Cohort study of molecular identification and typing of Mycobacterium abscessus, Mycobacterium massiliense, and Mycobacterium bolletii. J Clin Microbiol (2009) 2.58

Time to sputum culture conversion in multidrug-resistant tuberculosis: predictors and relationship to treatment outcome. Ann Intern Med (2006) 2.56

Dynamic population changes in Mycobacterium tuberculosis during acquisition and fixation of drug resistance in patients. J Infect Dis (2012) 2.53

Transfer of a Mycobacterium tuberculosis genotyping method, Spoligotyping, from a reverse line-blot hybridization, membrane-based assay to the Luminex multianalyte profiling system. J Clin Microbiol (2004) 2.53

Virulence of selected Mycobacterium tuberculosis clinical isolates in the rabbit model of meningitis is dependent on phenolic glycolipid produced by the bacilli. J Infect Dis (2005) 2.50

Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis. J Antimicrob Chemother (2009) 2.47

Differential monocyte activation underlies strain-specific Mycobacterium tuberculosis pathogenesis. Infect Immun (2004) 2.47

The W-Beijing lineage of Mycobacterium tuberculosis overproduces triglycerides and has the DosR dormancy regulon constitutively upregulated. J Bacteriol (2007) 2.42

SQ109 targets MmpL3, a membrane transporter of trehalose monomycolate involved in mycolic acid donation to the cell wall core of Mycobacterium tuberculosis. Antimicrob Agents Chemother (2012) 2.41

Rationally designed nucleoside antibiotics that inhibit siderophore biosynthesis of Mycobacterium tuberculosis. J Med Chem (2006) 2.37

Evaluation of the epidemiologic utility of secondary typing methods for differentiation of Mycobacterium tuberculosis isolates. J Clin Microbiol (2003) 2.34

Ambulatory blood pressure monitoring in 9357 subjects from 11 populations highlights missed opportunities for cardiovascular prevention in women. Hypertension (2011) 2.33

ethA, inhA, and katG loci of ethionamide-resistant clinical Mycobacterium tuberculosis isolates. Antimicrob Agents Chemother (2003) 2.31

Defining race/ethnicity and explaining difference in research studies on lung function. Eur Respir J (2012) 2.30

Prognostic value of isolated nocturnal hypertension on ambulatory measurement in 8711 individuals from 10 populations. J Hypertens (2010) 2.28

Prognostic superiority of daytime ambulatory over conventional blood pressure in four populations: a meta-analysis of 7,030 individuals. J Hypertens (2007) 2.26

High incidence of hospital admissions with multidrug-resistant and extensively drug-resistant tuberculosis among South African health care workers. Ann Intern Med (2010) 2.23

A consistent log-linear relationship between tuberculosis incidence and body mass index. Int J Epidemiol (2009) 2.20

Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis. Nat Med (2013) 2.19

Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis. Eur Respir J (2012) 2.17

Proteasomal protein degradation in Mycobacteria is dependent upon a prokaryotic ubiquitin-like protein. J Biol Chem (2008) 2.12

Succinate dehydrogenase mutation underlies global epigenomic divergence in gastrointestinal stromal tumor. Cancer Discov (2013) 2.11

Age-related susceptibility to infection with diarrheagenic Escherichia coli among infants from Periurban areas in Lima, Peru. Clin Infect Dis (2009) 2.09

Incidence and risk factors of peripheral arterial occlusive disease in a prospective cohort of 700 adult elderly men followed for 5 years. World J Surg (2010) 2.06

Community-based treatment of multidrug-resistant tuberculosis in Lima, Peru: 7 years of experience. Soc Sci Med (2004) 2.05

Treatment outcomes and survival based on drug resistance patterns in multidrug-resistant tuberculosis. Am J Respir Crit Care Med (2010) 2.04

HIV care and treatment factors associated with improved survival during TB treatment in Thailand: an observational study. BMC Infect Dis (2009) 2.00

The role of MmpL8 in sulfatide biogenesis and virulence of Mycobacterium tuberculosis. J Biol Chem (2004) 1.99

Interleukin 7 signaling in dendritic cells regulates the homeostatic proliferation and niche size of CD4+ T cells. Nat Immunol (2009) 1.98

Somatic mutations of ERBB2 kinase domain in gastric, colorectal, and breast carcinomas. Clin Cancer Res (2006) 1.98

Recurrent tuberculosis in the United States and Canada: relapse or reinfection? Am J Respir Crit Care Med (2004) 1.96

Prospects for new antitubercular drugs. Curr Opin Microbiol (2004) 1.94